These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21055895)

  • 1. Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia.
    Sheu WH; Chuang HC; Cheng SM; Lee MR; Chou CC; Cheng FC
    J Pharm Biomed Anal; 2011 Mar; 54(4):759-64. PubMed ID: 21055895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Luo Y; Yin W; Signore AP; Zhang F; Hong Z; Wang S; Graham SH; Chen J
    J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.
    Allahtavakoli M; Moloudi R; Arababadi MK; Shamsizadeh A; Javanmardi K
    Brain Res; 2009 May; 1271():121-7. PubMed ID: 19332033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study.
    Kim KB; Lee DJ; Yeo CW; Shin JG; Bae SK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(20-21):1951-6. PubMed ID: 19477697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive and selective liquid chromatography-mass spectrometry method for the quantification of rosiglitazone in human plasma.
    He J; Hu YF; Duan LF; Tan ZR; Wang LS; Wang D; Zhang W; Li Z; Liu J; Tu JH; Yao YM; Zhou HH
    J Pharm Biomed Anal; 2007 Jan; 43(2):580-5. PubMed ID: 16934427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke.
    Allahtavakoli M; Shabanzadeh AP; Sadr SS; Parviz M; Djahanguiri B
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1052-8. PubMed ID: 17042914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats.
    Wang CX; Ding X; Noor R; Pegg C; He C; Shuaib A
    J Cereb Blood Flow Metab; 2009 Oct; 29(10):1683-94. PubMed ID: 19553906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of a novel PPARγ partial agonist (S)-2-ethoxy-3-(4-{3-methyl-5-[4-(3-methyl-isoxazol-5-yl)-phenyl]thiophen-2-ylmethoxy}-phenyl)-propionic acid (PAM-1616) in rat plasma using liquid chromatography-tandem mass spectrometry.
    Chae HW; Jung H; Kim EJ; Shim HJ; Lim JI; Ji HY; Lee HS
    Arch Pharm Res; 2010 Sep; 33(9):1389-94. PubMed ID: 20945137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method.
    Abe M; Takiguchi Y; Ichimaru S; Kaji S; Tsuchiya K; Wada K
    Eur J Pharmacol; 2008 Jul; 589(1-3):215-9. PubMed ID: 18571644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study.
    Zhang L; Tian Y; Zhang Z; Chen Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jul; 854(1-2):91-8. PubMed ID: 17459785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients.
    Aramwit P; Supasyndh O; Sriboonruang T
    J Clin Pharm Ther; 2008 Dec; 33(6):685-90. PubMed ID: 19138247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
    Allahtavakoli M; Shabanzadeh A; Roohbakhsh A; Pourshanazari A
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):309-14. PubMed ID: 17910613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation.
    Villegas I; Martín AR; Toma W; de la Lastra CA
    Eur J Pharmacol; 2004 Nov; 505(1-3):195-203. PubMed ID: 15556153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
    Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
    Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Zhang XJ; Xiong ZB; Tang AL; Ma H; Ma YD; Wu JG; Dong YG
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):156-61. PubMed ID: 19566839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.
    Carreón-Torres E; Rendón-Sauer K; Monter-Garrido M; Toledo-Ibelles P; Gamboa R; Menjivar M; López-Marure R; Luc G; Fievet C; Cruz D; Vargas-Alarcón G; Pérez-Méndez O
    Clin Chim Acta; 2009 Mar; 401(1-2):37-41. PubMed ID: 19036342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide.
    Gonon AT; Bulhak A; Labruto F; Sjöquist PO; Pernow J
    Basic Res Cardiol; 2007 Jan; 102(1):80-9. PubMed ID: 16900441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys.
    Uchiyama M; Iwabuchi H; Tsuruta F; Abe K; Takahashi M; Koda H; Oguchi M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 Apr; 39(4):653-66. PubMed ID: 21177486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.